No Data
Changshan Pharmaceutical: 2024 Annual Results Forecast
Heparin centralized procurement not being selected has affected product sales. Hebei Changshan Biochemical Pharmaceutical expects a net loss in 2024 | Quick read announcement.
In 2024, Hebei Changshan Biochemical Pharmaceutical is expected to continue to report a loss in net income, but with a significant narrowing compared to 2023; previously, the company stated that there are currently no plans to conduct clinical trials for the weight loss indication of Abengutai injection.
Hebei Changshan Biochemical Pharmaceutical (300255.SZ): Expected loss of 0.12 billion yuan to -0.18 billion yuan for the year 2024.
On January 23, Gelonghui reported that Hebei Changshan Biochemical Pharmaceutical (300255.SZ) announced its performance forecast for 2024, expecting a profit loss of 0.12 billion to 0.18 billion yuan, with a net income loss of 0.16 billion to 0.22 billion yuan after deducting non-recurring gains and losses. Due to the impact of the centralized procurement policy for pharmaceuticals, the market share structure of domestic low molecular weight heparin preparations has changed. The company's main product, low molecular weight heparin calcium injection, did not enter the national centralized procurement. In 2024, sales of the company's main variety, low molecular weight heparin calcium injection, will continue to decline, and sales of other low molecular weight heparin preparations have not yet reached significant sales.
Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Is Making Moderate Use Of Debt
Some Shareholders Feeling Restless Over Hebei Changshan Biochemical Pharmaceutical Co., Ltd.'s (SZSE:300255) P/S Ratio
Hebei Changshan Biochemical Pharmaceutical (300255.SZ): Plans to conclude the "Annual production of 35 tons of heparin series Active Pharmaceutical Ingredient product project" and permanently supplement working capital with the surplus fundraising.
On December 11, Gelonghui reported that Hebei Changshan Biochemical Pharmaceutical (300255.SZ) announced that its fifth Board of Directors' eighteenth meeting and the fifth Supervisory Board's fourteenth meeting on December 11, 2024, reviewed and approved the proposal regarding the conclusion of the fundraising investment project and the permanent supplement of surplus raised funds to working capital, agreeing to conclude the fundraising investment project "Annual production of 35 tons of heparin series Active Pharmaceutical Ingredient products project" and permanently supplement the surplus raised funds to working capital.
Investor Optimism Abounds Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255) But Growth Is Lacking
